Bexarotene Shows Promise in Chemoprevention of Small Cell Lung Cancer

New research has shed light on the potential of bexarotene, a retinoid X receptor agonist, in the prevention of small cell lung cancer. A study conducted by researchers at the Washington University, Alvin J. Siteman Cancer Center, has revealed that bexarotene significantly reduced tumor incidence, number, and load in a genetically engineered mouse model of small cell lung carcinoma. The study's findings suggest that bexarotene may be a potent chemopreventive agent in this cancer type.

Key Takeaways:

• Bexarotene treatment reduced tumor incidence, number, and load in a genetically engineered mouse model of small cell lung carcinoma.
• Immunohistochemical staining indicated that bexarotene treatment decreased cell proliferation and increased apoptosis in tumors.
• The Rb1/p53 gene-targeted mouse model is a valuable tool for chemopreventive studies on human small cell lung cancer.
• Budesonide treatment showed a non-significant trend towards inhibition, but did not achieve statistical significance.
• The study highlights the potential of bexarotene as a chemopreventive agent in small cell lung cancer.

Statistics:

• 55% reduction in tumor incidence following bexarotene treatment (p < 0.05)
• 40% reduction in tumor number following bexarotene treatment (p < 0.05)
• 30% reduction in tumor load following bexarotene treatment (p < 0.05)
• 12 mice were used in the control group, while 15 mice were used in the bexarotene treatment group.

Sources:

• Wang, Y., et al. "Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer." Cancer Prevention Research. 2009;2(12):1059-64.
• Washington University, Alvin J. Siteman Cancer Center. (2009). "Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer."